HAVCR2 and neoplasm: TIM‐3 is distinctly perturbed among the CD8+PD1+ T and Treg cells within the tumor TME,48 and the blockade in a preclinical setting has been found to be effective in models of pancreatic cancer, colorectal cancer and NSCLC.49